CNPharm Co., Ltd.
10Patents
10Active
10Granted
52Portfolio score
Filing activity: Apr 28, 2009 → Aug 18, 2022 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10336867B2 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | Chemistry; Metallurgy | 4 | Active |
| US10584214B2 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | Chemistry; Metallurgy | 2 | Active |
| US10590243B2 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | Chemistry; Metallurgy | 2 | Active |
| US11180615B2 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | Chemistry; Metallurgy | 1 | Active |
| US12409229B2 | Synthesizing drug-organic-acid-anhydride conjugates without using coupling reagent | Chemistry; Metallurgy | 0 | Active |
| US11912829B2 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | Chemistry; Metallurgy | 0 | Active |
| US8344173B2 | Dendritic oligopeptide-grafteded cyclotriphosphazene, a process for the preparation thereof and a drug delivery system containing the same | Chemistry; Metallurgy | 0 | Active |
| US11969440B2 | Metal (hydr)oxide composite comprising poorly soluble drug, method for manufacturing same, and pharmaceutical composition comprising same | Emerging Cross-Sectional Technologies | 0 | Active |
| US12297213B2 | Metal hydroxide complex comprising modified multilayer hydroxide structure comprising active ingredient and method of manufacturing same | Emerging Cross-Sectional Technologies | 0 | Active |
| US12419961B2 | Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.